Last Update 29 Apr 26
Fair value Increased 22%GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook
Narrative Update on Genmab
The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.
Analyst Commentary
Recent Street research on Genmab clusters around two themes. On one side, several firms have turned more optimistic, with fresh upgrades and restarted coverage after recent acquisitions and an updated earnings outlook. On the other, some Bearish analysts are trimming expectations or taking a more neutral stance as they reassess execution risks and the outlook for key assets like Epkinly and petosemtamab.
Goldman Sachs has joined the more positive camp with an upgrade, while other firms have raised or reaffirmed Buy ratings alongside incremental price target changes around US$40 per share. At the same time, there are more cautious voices that focus on near term product expectations and integration risk around deals such as the Merus acquisition.
The mix of bullish and cautious calls leaves you with a split picture. Supportive analysts highlight the refreshed pipeline and potential catalysts around 2026. Bearish analysts focus on the durability of growth beyond existing royalty streams and the timing of new revenue contributions.
Bearish Takeaways
- Bearish analysts trimming the price target to US$40 from US$45 link this move to lowered near term Epkinly estimates, which points to concern about how quickly this asset can contribute against prior expectations.
- Resumed coverage at an Equal Weight rating with a US$34 price target after the Merus acquisition shows caution around deal execution and the risk that new assets like petosemtamab may not fully offset uncertainties tied to existing products.
- The tighter price target range around US$34 to US$41 signals that some Bearish analysts see limited upside versus current valuations, particularly as they factor in updated product models and acquisition related risks.
- References to a catalyst heavy 2026 also carry execution risk, since any delays or underwhelming data from programs such as Epkinly or petosemtamab could challenge the more constructive growth assumptions embedded in bullish models.
What's in the News
- Genmab reported new Phase 1/2 RAINFOL-01 data for rinatabart sesutecan (Rina-S) in combination with bevacizumab in advanced ovarian cancer, with a safety profile described as consistent with the known profiles of both agents and no new safety signals reported, including no ocular toxicities, peripheral neuropathy, interstitial lung disease or clinically significant bleeding (Key Developments).
- In the RAINFOL-01 combination cohort, the most common treatment emergent adverse events were nausea (80%), fatigue (67.5%), anemia (55%) and neutropenia (45%). Serious treatment emergent adverse events occurred in 15% of patients, dose reductions in 27.5% and treatment discontinuation in 5%, with no fatal treatment emergent adverse events reported (Key Developments).
- Rina-S is moving through an expanded late stage clinical program across several Phase 3 RAINFOL trials in ovarian and endometrial cancers, plus a Phase 2 study in non small cell lung cancer. The broader program targets cancers described as having unmet need, and safety and efficacy are not yet established (Key Developments).
- Lundbeck plans to present new data at the 2026 AD/PD conference on Lu AF28996, a D1/D2 receptor agonist for advanced Parkinson's disease, and on multiple system atrophy research that feeds into the amlenetug program, which is being developed under a joint research and licensing agreement between Lundbeck and Genmab (Key Developments).
- Genmab issued 2026 earnings guidance, with revenue expected in a range of US$4.1b to US$4.4b compared with US$3.7b in 2025, and operating profit expected in a range of US$0.9b to US$1.4b compared with US$1.3b in 2025. The company indicated that projected 2026 revenue is driven by higher royalties, net product sales and collaboration revenue, mainly related to DARZALEX and Kesimpta royalties (Key Developments).
Valuation Changes
- Fair Value: DKK 1,300.0 in the prior framework compared with DKK 1,588.21 in the updated model.
- Discount Rate: 5.84% previously, now set at 5.95% in the new assumptions.
- Revenue Growth: 15.38% in the earlier view compared with 17.01% in the latest update.
- Net Profit Margin: 24.29% in the prior case, now modeled at 18.77%.
- Future P/E: 9.58x in the previous setup compared with 14.82x in the updated valuation.
Key Takeaways
- Reliance on a few key oncology products and limited pipeline diversification exposes the company to significant competitive, regulatory, and exclusivity risks.
- Mounting pricing pressures and escalating research costs threaten profitability, making sustainable earnings growth dependent on successful new product launches.
- Strong pipeline, strategic partnerships, and global expansion position Genmab for sustained revenue growth and profitability, supported by secular healthcare trends and robust commercial execution.
Catalysts
About Genmab- A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
- Genmab's outsized exposure to future pricing pressure, as governments and payers globally move to control healthcare costs, may dramatically limit the company's ability to achieve premium pricing for novel oncology therapies like EPKINLY and Rina-S, directly capping revenue growth even if new indications are approved.
- Highly concentrated dependence on a few commercial assets-principally DARZALEX, EPKINLY, and Tivdak-and a continued lack of diversified late-stage wholly owned programs mean long-term earnings are at risk from loss of exclusivity, patent cliffs, or competitive displacement by next-generation therapies or biosimilars, threatening both future royalty streams and operating margins.
- Intensifying global regulatory scrutiny and uncertainty, combined with geopolitical tensions and evolving standards at agencies like the FDA, could significantly delay launches, restrict the scope of approvals, and require costlier, more complex post-marketing studies, resulting in lower near
- and long-term earnings.
- Competitive threats from emerging and incumbent biotechs as well as large pharma, many now focused on bispecifics and antibody platforms, increase the risk that Genmab's key assets may lose market share and pricing power faster than anticipated, sharply reducing anticipated product revenue trajectories and compressing net margins.
- Rapidly rising research and development costs-driven by expensive late-stage clinical programs and increasingly challenging regulatory demands-are weighing heavily on Genmab's operating leverage; without commensurate pipeline success and new major product launches, this will eventually erode profitability and constrain net earnings growth.
Genmab Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Genmab compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Genmab's revenue will grow by 17.0% annually over the next 3 years.
- The bearish analysts assume that profit margins will shrink from 25.9% today to 18.8% in 3 years time.
- The bearish analysts expect earnings to reach $1.1 billion (and earnings per share of $17.92) by about April 2029, up from $963.0 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $2.5 billion.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 15.0x on those 2029 earnings, down from 16.9x today. This future PE is greater than the current PE for the GB Biotechs industry at 10.4x.
- The bearish analysts expect the number of shares outstanding to decline by 2.72% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 5.95%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Genmab's strong financial position, including around $3 billion in cash and robust operating profit growth of 56% in the first half of 2025, provides significant flexibility for continued investment in R&D and expansion, supporting future revenue and sustained net profit.
- A rapidly advancing and broad pipeline, notably late-stage programs like EPKINLY, Rina-S, and acasunlimab, combined with positive pivotal trial results and accelerated regulatory filings, position Genmab for product-driven revenue growth and margin improvement as new products launch.
- Continued commercial success and uptake of recently launched proprietary assets, with EPKINLY and Tivdak showing global sales up 60% and 30% respectively year-over-year, along with regulatory approvals in more than 60 countries, contribute to recurring revenue and strengthen long-term earnings.
- Expanding reach into new indications and geographies for existing products, coupled with strategic collaborations and data-sharing with major pharma partners like AbbVie, increases the addressable market, underpins royalty and milestone income, and supports the sustainability of revenue and operating margins.
- Secular healthcare trends such as the aging global population, higher cancer prevalence, expanding access to biologics in emerging markets, and increased emphasis on targeted therapies all increase demand for Genmab's antibody technologies, creating tailwinds for long-term top-line growth and profitability.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Genmab is DKK1588.21, which represents up to two standard deviations below the consensus price target of DKK2342.95. This valuation is based on what can be assumed as the expectations of Genmab's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK3046.0, and the most bearish reporting a price target of just DKK1400.0.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $6.0 billion, earnings will come to $1.1 billion, and it would be trading on a PE ratio of 15.0x, assuming you use a discount rate of 6.0%.
- Given the current share price of DKK1690.0, the analyst price target of DKK1588.21 is 6.4% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Genmab?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
